In Regeneron Pharmaceuticals, Inc v Canada (AG), 2023 FC 768, the Federal Court granted Regeneron’s
application to add an inventor to its issued patent, which was the subject of pending litigation. The Court was satisfied, based on the evidence, that the omission of the inventor was made by inadvertence or mistake and not for the purpose of delay.
While Regeneron did not provide affidavits from the already named inventors, the Court noted that this was not a requirement, and that the balance of the evidence favoured granting the application. For example, the Court considered that the same amendment
to inventorship was accepted by the Canadian and US Patent Offices in respect of related patent applications.
Finally, the Court found that granting the application would not impact any third-party rights, as the parties to the ongoing litigation were notified of the application and did not seek to intervene.
Should you have any questions, please do not hesitate to contact a member of the Pharmaceutical Litigation Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
On February 7, 2024, the Federal Court dismissed Takeda’s action under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations in relation to dexlansoprazole (Takeda’s DEXILANT).Read More
On January 12, 2024, the Federal Court of Appeal (FCA) dismissed both appeals: Apotex Inc v Janssen Inc, 2024 FCA 9 and Pharmascience Inc v Janssen Inc, 2024 FCA 10.Read More
Federal Court of Appeal affirms paliperidone palmitate claims are not unpatentable methods of medical treatmentOn February 1, 2024, the Federal Court of Appeal (FCA) dismissed Pharmascience’s appeal. Per the FCA, whether a claimed dosing regimen is an unpatentable method of medical treatment cannot be based ex...Read More